This may indicate that the beneficial effect of combining amivantamab with chemotherapy compared to chemotherapy alone is evident regardless of prior lines of treatment in patients with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.